BCL2 and B-cell chronic lymphocytic leukemia: Navitoclax (ABT-263) is another early BCL-2 inhibitor that overcomes the poor bioavailability of ABT-737 and has shown single-drug antitumor effects on FL and CLL in preclinical and early clinical trials [13].